Investment House LLC Sells 575 Shares of Pfizer Inc. (NYSE:PFE)

Investment House LLC trimmed its position in shares of Pfizer Inc. (NYSE:PFE) by 2.2% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,305 shares of the biopharmaceutical company’s stock after selling 575 shares during the period. Investment House LLC’s holdings in Pfizer were worth $708,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also bought and sold shares of the business. Ironvine Capital Partners LLC boosted its stake in shares of Pfizer by 2.1% during the first quarter. Ironvine Capital Partners LLC now owns 16,953 shares of the biopharmaceutical company’s stock valued at $470,000 after purchasing an additional 353 shares during the period. Patrick M Sweeney & Associates Inc. grew its stake in Pfizer by 0.8% in the second quarter. Patrick M Sweeney & Associates Inc. now owns 42,162 shares of the biopharmaceutical company’s stock worth $1,180,000 after purchasing an additional 355 shares in the last quarter. Continuum Advisory LLC lifted its holdings in shares of Pfizer by 1.5% in the 2nd quarter. Continuum Advisory LLC now owns 25,185 shares of the biopharmaceutical company’s stock worth $705,000 after buying an additional 360 shares during the period. Advisor OS LLC grew its position in shares of Pfizer by 1.0% during the 4th quarter. Advisor OS LLC now owns 35,202 shares of the biopharmaceutical company’s stock worth $1,013,000 after buying an additional 365 shares in the last quarter. Finally, Lantz Financial LLC increased its stake in shares of Pfizer by 1.3% during the first quarter. Lantz Financial LLC now owns 30,582 shares of the biopharmaceutical company’s stock valued at $849,000 after buying an additional 381 shares during the period. Institutional investors own 68.36% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on PFE. Morgan Stanley lifted their target price on Pfizer from $28.00 to $29.00 and gave the company an “equal weight” rating in a research note on Thursday, May 2nd. BMO Capital Markets reaffirmed an “outperform” rating and set a $36.00 price target (up from $33.00) on shares of Pfizer in a research report on Thursday, May 2nd. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, Wells Fargo & Company lifted their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Stock Performance

Shares of NYSE PFE traded up $0.13 during trading on Wednesday, reaching $29.03. 16,580,738 shares of the company traded hands, compared to its average volume of 39,231,121. The stock has a market cap of $164.50 billion, a P/E ratio of -483.67, a PEG ratio of 1.00 and a beta of 0.69. The firm’s fifty day simple moving average is $28.78 and its 200 day simple moving average is $27.93. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $37.15.

Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business had revenue of $13.28 billion for the quarter, compared to analyst estimates of $12.96 billion. During the same quarter in the prior year, the firm posted $0.67 EPS. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. As a group, research analysts anticipate that Pfizer Inc. will post 2.68 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 5.79%. The ex-dividend date of this dividend is Friday, July 26th. Pfizer’s payout ratio is -2,800.00%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.